Outcomes of thrombolysis with and without predilation of the inferior vena cava (IVC) in patients with Budd-Chiari syndrome with old IVC thrombosis

Vasc Endovascular Surg. 2013 Apr;47(3):232-8. doi: 10.1177/1538574413478495. Epub 2013 Feb 14.

Abstract

Purpose: To compare the efficacy of thrombolysis with and without predilation of the inferior vena cava (IVC) for Budd-Chiari syndrome (BCS) with old IVC thrombosis.

Methods: We divided 40 patients with BCS with old IVC thrombosis into 2 groups, group A (n = 21), thrombolysis after dilation of the obstructed IVC and group B (n = 19), thrombolysis without predilation of the obstructed IVC. Thrombolysis was performed via urokinase administration through the dorsal vein of the foot.

Results: Color Doppler ultrasonography at 30 days showed complete resolution of the thrombus in 21 (100%) group A patients and 6 group B patients (31.6%; P < .001). Thrombolysis was achieved using a lower dose of urokinase and within a shorter time frame in group A than in group B (P < .001).

Conclusions: Thrombolysis after dilation was superior to thrombolysis alone and was safe and efficacious in patients with BCS with old IVC thrombosis.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Intravenous
  • Adult
  • Aged
  • Angioplasty, Balloon* / adverse effects
  • Angioplasty, Balloon* / instrumentation
  • Budd-Chiari Syndrome / diagnosis
  • Budd-Chiari Syndrome / drug therapy
  • Budd-Chiari Syndrome / therapy*
  • Chi-Square Distribution
  • Combined Modality Therapy
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Phlebography
  • Predictive Value of Tests
  • Thrombolytic Therapy* / adverse effects
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Doppler, Color
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Urokinase-Type Plasminogen Activator / adverse effects
  • Vascular Access Devices
  • Vena Cava, Inferior* / diagnostic imaging

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator